Evaxion Biotech Advances CMV Vaccine with AI Innovation
Company Announcements

Evaxion Biotech Advances CMV Vaccine with AI Innovation

Evaxion Biotech (EVAX) has released an update.

Evaxion Biotech has unveiled promising preclinical results for its cytomegalovirus vaccine program, EVX-V1, utilizing its AI-Immunology platform to trigger targeted immune responses. The innovative approach, which combines AI-identified antigens with a proprietary prefusion glycoprotein B antigen, marks a significant step towards developing an effective CMV vaccine. This development could potentially tap into the growing CMV treatment market, valued at $474.6 million in 2023, and poised for further growth.

For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyEvaxion Biotech announces preclinical data for CMV vaccine program EVX-V1
TipRanks Auto-Generated NewsdeskEvaxion Biotech Reports Q3 Progress and Financials
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App